CJC-1295 no DAC (5MG)

CJC-1295 no DAC — the unmodified short-half-life GHRH analog — supplied by BioFusion as a vacuum-sealed lyophilized 5mg vial for GHRH-pathway research chemistry where short kinetics are preferred.

Research context

CJC-1295 no DAC is the parent GHRH-analog peptide without the DAC (Drug Affinity Complex) maleimidopropionyl modification at the N-terminus. The absence of DAC results in a shorter research-half-life — useful in pulse-protocol comparative-chemistry studies and fast-on/fast-off receptor-binding research. Pair with the DAC-modified long-acting form in cross-kinetics research panels.

Synthesis & documentation

Produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility. Each lot is verified for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), moisture (Karl Fischer), and counter-ion (ion chromatography). The signed Certificate of Analysis ships with every order; lot history archived in the COA library.

Storage & handling

Lyophilized CJC-1295 no DAC is stable at −20 °C for the printed shelf life. After reconstitution, the standard 14-day-at-2-8 °C reference window applies; avoid freeze-thaw cycling. The BioFusion reconstitution calculator simplifies working-concentration math.

Why BioFusion

The “no DAC” form is sometimes confused with the DAC-modified form on third-party listings — a meaningful difference at the research level. BioFusion’s no-DAC reference is verified by LC-MS to confirm the absence of the modification at every release, with HPLC-purity ≥99.0%. Batch transparency ledger publishes synthesis-date per lot. Bulk discounts at three+ vials; members save 25% plus free U.S. shipping for 365 days.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.